# OR4F6

## Overview
The OR4F6 gene encodes the protein olfactory receptor family 4 subfamily F member 6, which is part of the olfactory receptor family. These receptors are a subset of G-protein-coupled receptors (GPCRs) that are primarily involved in the detection of odor molecules, playing a crucial role in the sense of smell. The OR4F6 protein is characterized by its seven-transmembrane domain structure, typical of GPCRs, which allows it to interact with odorant molecules and initiate a signal transduction pathway. While the primary function of OR4F6 is related to olfaction, recent studies have identified its potential involvement in metabolic processes, particularly in relation to early-onset type 2 diabetes mellitus and metabolic syndrome, suggesting a broader physiological role beyond olfactory perception (Yamada2018Identification).

## Clinical Significance
The OR4F6 gene has been identified as a novel susceptibility locus for early-onset type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in Japanese populations. A specific single nucleotide polymorphism (SNP) within OR4F6, rs141569282, has shown a significant association with these conditions. This SNP is linked to various metabolic traits, including blood hemoglobin A1c levels, which suggests a potential role in glucose metabolism (Yamada2018Identification). The allele odds ratio for this SNP indicates a potential protective effect against T2DM, highlighting its clinical significance in genetic risk assessment for these metabolic disorders (Yamada2018Identification).

Despite these findings, OR4F6 has not been previously associated with T2DM or related traits in genome-wide association studies, suggesting its novelty as a genetic marker for these conditions (Yamada2018Identification). The clinical implications of OR4F6 mutations are not fully understood, and further research is needed to elucidate the mechanisms by which this gene influences metabolic disorders. The study's findings underscore the importance of genetic components in the pathogenesis of early-onset T2DM and MetS, although the broader clinical significance of OR4F6 mutations remains to be determined (Yamada2018Identification).


## References


[1. (Yamada2018Identification) Yoshiji Yamada, Kimihiko Kato, Mitsutoshi Oguri, Hideki Horibe, Tetsuo Fujimaki, Yoshiki Yasukochi, Ichiro Takeuchi, and Jun Sakuma. Identification of four genes as novel susceptibility loci for earlyâ€‘onset type 2 diabetes mellitus, metabolic syndrome, or hyperuricemia. Biomedical Reports, May 2018. URL: http://dx.doi.org/10.3892/br.2018.1105, doi:10.3892/br.2018.1105. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/br.2018.1105)